The 30-second summary
- In the STEP 1 Extension trial, stopping semaglutide led to regaining about two-thirds of the weight lost within 12 months.
- The drug treats appetite; without the drug, appetite returns. The body's set point is biological, not motivational.
- A subset of women keep the weight off long-term. The pattern across studies: those who built robust food habits, kept resistance training, and maintained a clear calorie awareness during the drug period.
What the trial actually showed
The STEP 1 Extension study published in Diabetes, Obesity and Metabolism in 2022 followed participants from the original STEP 1 trial of semaglutide after their treatment ended. They had lost an average of 17.3% of body weight by week 68 on the drug. At week 120, one year after discontinuation, they had regained about 11.6% of their body weight. (Wilding JPH et al., DOM 2022.)
That is roughly two-thirds of the weight loss back, on average, in a year.
Tirzepatide showed a similar pattern in the SURMOUNT-4 trial: participants who switched from active drug to placebo regained substantial weight within 12 months, while those who continued the drug maintained their loss. (Aronne LJ et al., JAMA 2024.)
This is not a failure. This is a feature of how GLP-1s work, they treat the symptoms of appetite dysregulation and metabolic set point, not the underlying biology. When the treatment stops, the underlying biology returns.
Why the weight comes back
Three mechanisms, all observable:
- Hunger comes back to baseline within weeks. The appetite suppression of a GLP-1 fades over four to six weeks after the last dose. Most women report feeling "the old hunger" returning before the scale has moved.
- Metabolic rate has adapted downward. After significant weight loss, your daily energy expenditure is lower than it was at your previous body weight, not just because you are smaller, but because the body actively defends against weight loss with slowed metabolism. (Rosenbaum M, Leibel RL, Int J Obes 2010.)
- The set point is biological. A growing body of research suggests the body has a defended weight range, regulated by leptin, ghrelin, and other hormones. The GLP-1 shifts that defence point while you are on it. When you come off, the body works to return to its prior defended weight.
This is the same reason every weight-loss intervention, diets, programmes, even bariatric surgery to some extent, shows weight regain on average. GLP-1s are not unique. They are just honest about it.
Who keeps the weight off
Across the published literature on weight maintenance, certain patterns appear in the women who do not regain, or who regain less than the average:
- They maintained 1.2+ g/kg of protein daily during and after the drug, preserving muscle. Lean mass is a major driver of resting metabolic rate; preserved muscle means a higher daily burn.
- They continued resistance training. Two to three sessions per week, every week, indefinitely.
- They built food habits that did not depend on the drug. Vegetable-and-protein-anchored meals, low alcohol, consistent meal timing. These habits transfer.
- They monitored their weight weekly, not aspirationally. A 3 kg regain noticed at week 6 is much easier to address than a 15 kg regain noticed at month 12.
- They had access to the drug again if needed. The most realistic model is not "stop forever," it is "off for a stretch, back on if the curve drifts." This is medical management, not willpower.
The unifying theme: the women who maintain treat weight management like a chronic-disease problem, not a finite project.
The maintenance plan worth asking for
If you and your prescriber are talking about coming off, a real maintenance plan has four parts.
1. Off-ramp, not a cliff
For some women, a slower taper, half the dose for a few months before stopping entirely, softens the rebound. The evidence is anecdotal but the practice is widespread. Ask your prescriber.
2. A floor weight and a trigger weight
Write down two numbers:
- Your maintenance target. The weight you want to hold.
- Your trigger weight. Usually maintenance + 3 kg or 5% of body weight. The weight at which you and your prescriber will have a real conversation about whether to restart.
Both numbers in writing. Both reviewed every three months.
3. The non-negotiable habits
Pick three. Examples:
- Weigh yourself every Monday morning
- Eat 100+ grams of protein every day
- Two strength sessions per week, minimum
- A weekly average calorie target, tracked
The point is not the specific list. The point is committing in advance to a small, defined behavioural floor.
4. A re-entry plan
If your weight passes your trigger threshold and stays there for two consecutive months, what happens next? The conversation with your prescriber happens before you cross the line, not after. The plan might be: restart at a lower dose, restart at the previous max dose, switch to a different drug, or stay off and intensify the habits.
The argument for staying on
For many women, the data and the lived experience both support staying on the medication long-term, at the lowest effective dose. Hypertension medication is rarely seen as a personal failure. Type-2 diabetes medication is not stigmatised. Obesity medication is, but the biology is the same: a chronic condition with a chronic treatment.
Long-term safety data for GLP-1s now extends to a decade-plus (for the older drugs in the class). The risk-benefit calculation for staying on, at a maintenance dose, may be more favourable than coming off for many women.
This is a conversation with your prescriber, not a decision to make from an article.
What this is not
Stopping a GLP-1 is not a moral question. It is a medical question. The framing matters: "I stopped and the weight came back" is not the failure of you. It is the predictable behaviour of a biological system that the drug was managing.
What Steady does with this
If you stop your medication in Steady, you can keep tracking weight, protein, and habits without the dose log. The progress view continues to show the four-week moving average. The trigger-weight feature lets you set a number and get notified when you approach it. The off-the-drug period is not less data; it is the most important data for what comes next.
Sources
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 Extension). Diabetes Obes Metab 2022. DOM
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024. JAMA
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes 2010. PubMed
- Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. NEJM 2011. NEJM
Medical disclaimer: Decisions to stop, continue, or restart a medication are conversations with your prescriber. See our full medical disclaimer.